PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)...
Read More Details
Finally We wish PressBee provided you with enough information of ( RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation )
Also on site :
- Andrea Fuder, Chief Purchasing Officer at Volvo Group has tragically passed away
- Romania holds runoff vote in presidential election rerun
- Lawyer admits ‘embarrassing’ mistake after Anthropic’s Claude made up a source in a legal filing—and no one caught it